MCL-509 Indirect comparison of efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL)

Shah, B., Challagulla, S., Xu, S. et al. (5 more authors) (2024) MCL-509 Indirect comparison of efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL). In: Clinical Lymphoma Myeloma and Leukemia. Society of Hematologic Oncology 2024 Annual Meeting, 04-07 Sep 2024, Houston, Texas. Elsevier BV, S516-S517. ISSN: 2152-2650. EISSN: 2152-2650.

Metadata

Item Type: Proceedings Paper
Authors/Creators:
Copyright, Publisher and Additional Information:

© 2024 Elsevier Inc.
Keywords: MCL; mantle cell lymphoma; Bruton tyrosine kinase inhibitors; zanubrutinib; simulated treatment comparison; comparative efficacy
Dates:
  • Published (online): September 2024
  • Published: September 2024
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine and Population Health
Date Deposited: 19 Jan 2026 15:32
Last Modified: 19 Jan 2026 15:34
Status: Published
Publisher: Elsevier BV
Refereed: Yes
Identification Number: 10.1016/s2152-2650(24)01602-1
Related URLs:
Open Archives Initiative ID (OAI ID):

Export

Statistics

View Altmetric information about this item.


CORE (COnnecting REpositories)